지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2019.1
- 수록면
- 502 - 509 (8page)
이용수
초록· 키워드
오류제보하기
Purpose We tried to evaluate whether there are any specific features in treatment outcomes of firstline afatinib in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), compared with gefitinib or erlotinib. Materials and Methods We analyzed patients treated with first-line afatinib, gefitinib, or erlotinib for advanced EGFRmutant NSCLC at Samsung Medical Center between 2014 and 2016. Results In total, 467 patients received first-line afatinib (n=165), gefitinib (n=230), or erlotinib (n=72). Afatinib was used more often in patients with tumors harboring deletion in exon 19 (Del19), whereas the gefitinib group had more elderly, females, and never smokers. The median progression-free survival (PFS) time for afatinib, gefitinib, and erlotinib was 19.1 months, 13.7 months, and 14.0 months, respectively (p=0.001). The superior PFS of afatinib was more remarkable in subgroups of Del19 or uncommon EGFR mutations. Overall toxicity profiles of the three drugs were comparable, though more grade 3 or 4 toxicities were detected in afatinib (7.3%) compared with gefitinib (2.6%) or erlotinib (1.8%). The common grade 3 or 4 toxicities of afatinib included diarrhea (3.0%), paronychia (2.4%), and skin rash (1.8%). Dose modification was more frequently required in patients treated with afatinib (112/165, 68%), compared with gefitinib (5/230, 2%) and erlotinib (4/72, 6%). Interestingly, however, dose reduction in the afatinib group did not impair its efficacy in terms of PFS (dose reduction vs. no reduction group, 23.5 months vs. 12.4 months). Conclusion First-line afatinib showed satisfactory efficacy data and manageable toxicity profiles.
목차
등록된 정보가 없습니다.
참고문헌 (19)
참고문헌 신청
Torre LA / 2015 / Global cancer statistics, 2012 / CA Cancer J Clin 65:87~108
Mok TS / 2009 / Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma / N Engl J Med 361:947~957
Zhou C / 2011 / Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer(OPTIMAL, CTONG-0802) : a multicentre, open-label, randomised, phase 3 study / Lancet Oncol 12:735~742
Li D / 2008 / BIBW2992, an irreversible EGFR/HER2inhibitor highly effective in preclinical lung cancer models / Oncogene 27:4702~4711
Sequist LV / 2013 / Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations / J Clin Oncol 31:3327~3334
Mok TS / 2009 / Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma / N Engl J Med 361:947~957
Zhou C / 2011 / Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer(OPTIMAL, CTONG-0802) : a multicentre, open-label, randomised, phase 3 study / Lancet Oncol 12:735~742
Li D / 2008 / BIBW2992, an irreversible EGFR/HER2inhibitor highly effective in preclinical lung cancer models / Oncogene 27:4702~4711
Sequist LV / 2013 / Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations / J Clin Oncol 31:3327~3334
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma
Cancer Research and Treatment
2022 .04
-
The Role of Brain Radiotherapy Before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non–Small Cell Lung Cancer
Cancer Research and Treatment
2023 .04
-
Low-dose Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibition of EGFR Mutation-positive Lung Cancer: Therapeutic Benefits and Associations Between Dosage, Efficacy and Body Surface Area
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR–Tyrosine Kinase Inhibitors
Cancer Research and Treatment
2017 .01
-
EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy
Cancer Research and Treatment
2019 .01
-
Gefitinib 내성 후 Erlotinb과 한방 치료를 병행하여 호전된 뇌전이를 동반한 재발성 L858R 변이 비소세포폐암 환자 1례
대한한방내과학회지
2022 .10
-
The Prognostic Value of the Tumor Shrinkage Rate for Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Receiving Gefitinib
Tuberculosis and Respiratory Diseases
2015 .01
-
Incorporating Erlotinib or Irinotecan Plus Cisplatin into Chemoradiotherapy for Stage III Non-small Cell Lung Cancer According to EGFR Mutation Status
Cancer Research and Treatment
2017 .01
-
The Efficacy and Safety of Platinum/Vinorelbine as More Than Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer
Cancer Research and Treatment
2015 .01
-
Successful Treatment with Empirical Erlotinib in a Patient with Respiratory Failure Caused by Extensive Lung Adenocarcinoma
Acute and Critical Care
2016 .01
-
Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for patient with leptomeningeal metastasis of epidermal growth factor receptor mutant non-small cell lung cancer
Journal of Yeungnam Medical Science
2016 .06
-
EGFR Mutation Genotype Impact on the Efficacy of Pemetrexed in Patients with Non-squamous Non-small Cell Lung Cancer
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for patient with leptomeningeal metastasis of epidermal growth factor receptor mutant non-small cell lung cancer
영남의대학술지
2016 .01
-
Comparison of Clinicopathogenomic Features and Treatment Outcomes of EGFR and HER2 Exon 20 Insertion Mutations in Non–Small Cell Lung Cancer: Single-Institution Experience
Cancer Research and Treatment
2024 .07
-
Pemetrexed-Erlotinib, Pemetrexed Alone, or Erlotinib Alone as Second-Line Treatment for East Asian and Non-East Asian Never-Smokers with Locally Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer: Exploratory Subgroup Analysis of a Phase II Trial
Cancer Research and Treatment
2015 .01
-
The application of transgenic mice with mutant EGFR in drug development and biological role
한국실험동물학회 학술발표대회 논문집
2022 .01
-
Epidermal Growth Factor Receptor Mutation Status in the Treatment of Non-small Cell Lung Cancer: Lessons Learned
Cancer Research and Treatment
2015 .01
-
Dose-Response Relationship between Radiation Dose and Loco-regional Control in Patients with Stage II-III Esophageal Cancer Treated with Definitive Chemoradiotherapy
Cancer Research and Treatment
2017 .07
-
High-Dose Thoracic Re-irradiation of Lung Cancer Using Highly Conformal Radiotherapy Is Effective with Acceptable Toxicity
Cancer Research and Treatment
2019 .01
-
Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer
Cancer Research and Treatment
2016 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0